Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

How retatrutide works: three receptors

Retatrutide activates GIP, GLP-1 and glucagon receptors, combining appetite and glucose signals with a proposed energy-expenditure effect.

Why we wrote this. Triple agonist is easy to repeat and hard to explain. This piece separates receptor rationale from effects actually measured in people.

In this article (7 sections)
  1. How retatrutide works at three receptors
  2. The GLP-1 arm: appetite and glucose
  3. The GIP arm: a second meal signal
  4. The glucagon arm: the unusual addition
  5. What the human trials can show
  6. Why more receptors do not mean better by default
  7. What we do not yet know

Retatrutide works by switching on three hormone receptors with one peptide: GIP, GLP-1 and glucagon receptors. A receptor is a protein that receives a biological signal. An agonist is a molecule that activates it. This three-part design is why retatrutide is called a triple agonist. The plain-English idea is to combine signals that affect appetite and blood glucose with a glucagon signal that may add energy expenditure. The important caveat is that scientists cannot yet assign a precise share of the human effect to each receptor.

How retatrutide works at three receptors

The discovery paper describes LY3437943, retatrutide's development code, as having balanced laboratory activity at the glucagon and GLP-1 receptors, with greater activity at the GIP receptor[1]. Laboratory activity means how strongly the molecule activates receptors in an experimental system. It helps describe the design, but it does not translate directly into a percentage of weight loss or blood-glucose change in a person.

The pharmacokinetic profile, meaning the pattern of drug exposure over time, supported once-weekly administration in early human testing. A weight reduction remained visible through day 43 after one administration in that small Phase 1 programme[1]. This showed that the engineered peptide lasted long enough to test weekly. It did not establish an authorised schedule, because retatrutide is still investigational.

The GLP-1 arm: appetite and glucose

GLP-1 stands for glucagon-like peptide 1, a hormone released after food reaches the gut. Activating its receptor helps the pancreas release insulin when glucose is elevated. It also slows stomach emptying and sends fullness signals through the nervous system. In an obesity medicine, the practical result is usually less hunger and lower energy intake, alongside better post-meal glucose control.

This is the closest link to established GLP-1 medicines such as semaglutide. It also helps explain why gastrointestinal events are common in the retatrutide trials. Nausea, diarrhoea, vomiting and constipation were the leading events in the Phase 2 obesity programme, and they increased with dose[2]. A shared receptor pathway can create familiar effects without making the medicines interchangeable.

The GIP arm: a second meal signal

GIP stands for glucose-dependent insulinotropic polypeptide. It is another gut hormone released around meals. Its name describes one clear action: it supports insulin release when glucose is present. Its role in body-weight regulation is less intuitive because GIP signalling also acts in fat tissue and the nervous system. In a multi-receptor medicine, the GIP arm is meant to work with GLP-1 rather than operate as a separate drug.

This makes tirzepatide the closest approved analogue. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds a glucagon-receptor arm to that dual design. The comparison is useful for understanding the family tree, but there has not been a completed published head-to-head result showing exactly what the third arm adds.

The glucagon arm: the unusual addition

Glucagon is often introduced as insulin's opposite because it tells the liver to release stored glucose. That description is true but incomplete. Glucagon-receptor activity can also increase energy use. This creates the central design problem for a triple agonist: capture a possible energy-expenditure effect without losing glucose control. The GLP-1 and GIP arms support insulin responses while the glucagon arm adds a different metabolic signal.

In mice with obesity, Lilly researchers reported that glucagon-receptor-driven energy expenditure added to the reduction in calorie intake linked to GIP and GLP-1 receptor activity[1]. That experiment supports the rationale. It does not prove that human weight loss can be divided into an appetite fraction and an energy-expenditure fraction using the same proportions.

What the human trials can show

The Phase 2 obesity trial recorded a mean 24.2% body-weight reduction at 48 weeks in the 12 mg group, compared with 2.1% on placebo[2]. A separate Phase 2 trial in type 2 diabetes found dose-dependent reductions in HbA1c, a marker of average blood glucose, and body weight. The 12 mg escalation group had a 2.02 percentage-point HbA1c reduction at week 24 and a 16.94% weight reduction at week 36[3].

These trials demonstrate the combined molecule's observed effects in selected populations. They do not isolate one receptor at a time. There was no retatrutide arm with the glucagon activity switched off and everything else held equal. Claims that the glucagon arm alone caused a specific number of percentage points therefore go beyond the clinical design.

Why more receptors do not mean better by default

Adding a target can add effects and uncertainty. Both Phase 2 programmes reported dose-dependent heart-rate increases. In the obesity trial, the increase peaked around week 24 and then declined[2]. The published abstracts do not establish that one receptor alone caused this signal. Long-term cardiovascular and kidney outcomes are being tested separately.

Retatrutide has no approved indication, label or consumer dose. The FDA says it has not been found safe and effective for any condition and cannot be used in compounding under federal law[4]. Mechanism explains the research idea. It does not turn products sold online under the name into the trial medicine. The US regulatory page covers that distinction.

What we do not yet know

Researchers do not yet know how much of retatrutide's human effect comes from each receptor or whether the receptor balance is the best possible one. Completed outcomes data are also missing for heart attacks, strokes and kidney disease progression. Phase 3 results can define efficacy and safety more clearly, but even large trials will describe the whole molecule rather than offer a clean percentage contribution for each arm.

The safest short version is this: retatrutide combines the dual GIP and GLP-1 logic used by tirzepatide with an added glucagon signal. Animal work supports a mix of lower intake and higher energy expenditure. Human trials show weight and glucose changes from the combined drug, not a settled three-way breakdown of the mechanism.

Frequently asked

Which three receptors does retatrutide activate?

Retatrutide activates the GIP, GLP-1 and glucagon receptors. Its discovery paper reported balanced laboratory activity at the glucagon and GLP-1 receptors, with greater activity at the GIP receptor.

How is retatrutide different from tirzepatide?

Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates those two and adds the glucagon receptor. That makes tirzepatide the closest approved analogue, though the molecules have not yet produced a completed published head-to-head result.

Does retatrutide speed up metabolism?

Mouse experiments support increased energy expenditure from the glucagon-receptor component, alongside reduced calorie intake from the GIP and GLP-1 components. Human trials have not cleanly separated those contributions, so a precise metabolism claim would overstate the evidence.

Is retatrutide an approved GLP-1 medicine?

No. Retatrutide includes GLP-1 receptor activity, but it is an investigational triple agonist. The FDA says it has not been found safe and effective for any condition and cannot be used in compounding under federal law.

Sources

  1. [1]Coskun et al. (2022): LY3437943 from discovery to clinical proof of concept (PMID 35985340)Tier 1 · primary↩
  2. [2]Jastreboff et al. (2023): Phase 2 retatrutide obesity trial (PMID 37366315)Tier 1 · primary↩
  3. [3]Rosenstock et al. (2023): Phase 2 retatrutide type 2 diabetes trial (PMID 37385280)Tier 1 · primary↩
  4. [4]FDA: concerns with unapproved GLP-1 drugs, including retatrutideTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars